J&J leans on Tremfya, cancer drugs to overcome Stelara losses

BioPharma Dive

A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street s expectations and surpass $15 billion in first-quarter drug sales.

CommercialImmunology & InflammationRead full story